Holen Sie sich die Stockscreener-App
18.45
1.99%
0.36
Handel nachbörslich:
18.69
0.24
+1.30%
Schlusskurs vom Vortag:
$18.09
Offen:
$18.24
24-Stunden-Volumen:
157.47K
Relative Volume:
0.13
Marktkapitalisierung:
$96.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.12M
KGV:
-23.96
EPS:
-0.77
Netto-Cashflow:
$-6.82M
1W Leistung:
+10.74%
1M Leistung:
+235.45%
6M Leistung:
+2,925%
1J Leistung:
+6,048%
1-Tages-Spanne:
$17.52
$18.74
1-Wochen-Bereich:
$16.25
$19.70
52-Wochen-Spanne:
$0.2739
$38.50
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Vergleichen Sie MNPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| MNPR | 18.45 | 96.32M | 0 | -7.12M | -6.82M | -0.77 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
HC Wainwright Has Positive Estimate for MNPR FY2024 Earnings - MarketBeat
HC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price - MarketBeat
Monopar Therapeutics stock target lifted, buy rating on AstraZeneca deal By Investing.com - Investing.com UK
Monopar Therapeutics (NASDAQ:MNPR) Releases Financial Results for the Third Quarter 2024Monopar Therapeutics Inc. recently disclosed its financial results for the third quarter ending September 30, 2024, in a press release dated November 8, 2024. The - Defense World
MNPRMonopar Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Monopar Therapeutics Inc Reports Q3 2024 GAAP EPS of -$0.37 and Net Loss of $1.3 Million - GuruFocus.com
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - The Manila Times
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - GlobeNewswire Inc.
Janus Henderson Group PLC Acquires New Stake in Monopar Therapeu - GuruFocus.com
RA Capital Management, L.P. Acquires New Stake in Monopar Therap - GuruFocus.com
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - The Manila Times
Insider Purchase: CFO Karthik Radhakrishnan Acquires Shares of M - GuruFocus.com
Monopar Therapeutics Closes $19.2 Million Stock Offering - TipRanks
Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share - MSN
(MNPR) Investment Analysis - Stock Traders Daily
Monopar Therapeutics announces public stock offering By Investing.com - Investing.com Nigeria
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock - The Manila Times
Monopar Therapeutics announces public stock offering - Investing.com
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock - The Manila Times
Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Drop in Short Interest - MarketBeat
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners are retail investors who got richer after stock soared 208% last week - Simply Wall St
Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week - Yahoo Finance
Monopar Therapeutics Skyrockets 400% on Licensing Deal - MSN
Wilmette startup's stock soars as it buys back the drug its founder made from Big Pharma - Crain's Chicago Business
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap DownHere's What Happened - MarketBeat
What's Going On With Monopar Therapeutics Shares Friday? - Benzinga
Monopar Therapeutics Secures License for Wilson Disease Treatment - Yahoo Finance
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
MNPR,NTLA,CPRI,WDC,TSLA: Top 5 Trending Stocks TodayMonopar Therapeutics (NASDAQ:MNPR), Capri Holdings (NYSE:CPRI) - Benzinga
Monopar Therapeutics Inc. has entered into an agreement to acquire worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. - Marketscreener.com
Health Care Down Amid Mixed Drug Developments -- Health Care Roundup - MarketWatch
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.33% - MSN
Viking Therapeutics stock soars on heels of Q3 beat - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Hits New 52-Week HighStill a Buy? - MarketBeat
Monopar secures global license for Wilson disease drug - Investing.com
Monopar retrieves Wilson disease candidate from AstraZeneca's scrap heap - Fierce Biotech
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines - Yahoo Finance
Monopar Therapeutics, Energy Vault Holdings, FREYR Battery: 3 Stocks Retailers Are Most Bullish Thursday Afternoon - Barchart
Why Is Monopar Therapeutics Stock Surging Over 400% On Thursday?AstraZeneca (NASDAQ:AZN), Monopar Therapeutics (NASDAQ:MNPR) - Benzinga
Monopar Up 450%Were You On Board? - RTTNews
Monopar Therapeutics (MNPR) Shares Surge on Partnership with Ale - GuruFocus.com
Monopar (MNPR) Experiences Stock Boost After An Agreement - Stocks Telegraph
Monopar Shares Surge on AstraZeneca Licensing Deal -- Update - MarketWatch
Monopar stock soars to 52-week high, hits $8.75 - Investing.com
Monopar secures global license for Wilson disease drug By Investing.com - Investing.com South Africa
Monopar Shares Rise on AstraZeneca Licensing Deal - Marketscreener.com
Monopar stock climbs as it takes over Wilson disease drug candidate (NASDAQ:MNPR) - Seeking Alpha
Monopar Therapeutics Inc Announces Agreement with Alexion, AstraZeneca Rare Disease for Late-Stage Wilson Disease Drug Candidate - Marketscreener.com
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Monopar Therapeutics Unveils Promising Radiopharmaceutical Data - TipRanks
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 - The Manila Times
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):